Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19
specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) …

IMPORTANCE The effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab,
and sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is …

Introduction Rapid, continuous implementation of credible scientific findings and regulatory
approvals is often slow in large, diverse health systems. The coronavirus disease 2019 (…

Background Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization
and death compared to placebo in patients with mild to moderate COVID-19; however, …

Background Neutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease
hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is …

Outpatient treatments that limit progression to severe coronavirus disease 2019 (COVID-19)
are of vital importance to optimise patient outcomes and public health. Monoclonal …

Monoclonal antibody (mAb) therapy can improve coronavirus disease 2019 outcomes when
infused early in select patients. We sought to rapidly create and implement a program for …

… Erin K McCreary PharmD; J Ryan Bariola MD; Tami Minnier MS; Richard J Wadas MD;
Judith A Shovel BSN; Debbie L Albin BS; Oscar C Marroquin MD; Kevin E Kip PhD; Kevin …